Acta Med. 2003, 46: 85-89
https://doi.org/10.14712/18059694.2019.12
Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
References
1. C, Loos M, Sels A et al. Detection of major bcr-abl expression at a very low level in blood cells of some healthy individuals. Blood 1995; 86:118–22.
2. MV, Fojo T, Bhalla KN et al. The Hsp 90 inhibitor geldamycin selectively sensitizes Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy. Leukemia 2001; 15:1537–43.
<https://doi.org/10.1038/sj.leu.2402257>
3. S, Rudzki Z, Walsh S et al. High frequency of point mutations clustered within the adenosine tri-phosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who developed imatinib (STI 571) resistance. Blood 2002; 99:3472–5.
<https://doi.org/10.1182/blood.V99.9.3472>
4. JE, Talpaz M, Giles F et al. High-dose imatinib mesylate (STI 571, Gleevec) in patients with chronic myeloid leukemia (CML) resistant or intolerant to interferon- alpha (IFN) induces molecular remission. Blood 2002; 100:Abstr. 616.
<https://doi.org/10.1182/blood-2002-10-3154>
5. GQ, Van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the Ph 210 bcr/abl gene of the Philadelphia chromosome. Science 1990; 247:824–30.
<https://doi.org/10.1126/science.2406902>
6. MW, Goldman JM, Lydon N et al. The tyrosine kinase inhibitor CGP 57148B selectively inhibits the growth of BCR-ABL positive cells. Blood 1997; 90:3691–8.
7. NJ, Wu JY, Stapley J et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI 571. Blood 2003; 101:690–8.
<https://doi.org/10.1182/blood.V101.2.690>
8. NJ, WU JY, Talpaz M. Novel tyrosine kinase inhibitors suppress BCRABL signaling and induce apoptosis in STI 571 sensitive and resistant CML cells. Blood 2002; 100:Abstr. 1434.
9. BJ. for IRIS (International Randomized INF vs STI-571 (Gleevec, Glivec, imatinib) versus interferon (INF) + cytarabin as initial therapy for patients with CML: results of randomized study. Proc Am Soc Clin Oncol 2002; 21:1a (Abstract).
10. JF, Cunnick JM, Lanchart R et al. Interleukin-3 protects Bcr-Abl-transformed hematopoietic progenitor cells from apoptosis induced by Bcr-Abl tyrosine kinase inhibitors. Leukemia 2002; 16:1589–95.
<https://doi.org/10.1038/sj.leu.2402678>
11. BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000; 105:3–7.
<https://doi.org/10.1172/JCI9083>
<PubMed>
12. BJ, Sawyers CL, Katarjian H. Activity of a specific inhibitor of the BCRABL tyrosine kinase in the blast crises of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia Chromosome. N Engl J Med 2001; 344:1038–42.
<https://doi.org/10.1056/NEJM200104053441402>
13. BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344:1031–7.
<https://doi.org/10.1056/NEJM200104053441401>
14. BJ, Tamura S, Buchdunger E et al. Effect of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells. Nature Medicine 1996; 2:561–6.
<https://doi.org/10.1038/nm0596-561>
15. S, Talpaz M, Estrov Z et al. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341:164–72.
<https://doi.org/10.1056/NEJM199907153410306>
16. C, Barni R, le Contre P et al. Role of alpha-1 acid glycoprotein in the in-vivo resistance of human Bcr-Abl+ leukemic cells to the Abl inhibitor STI 571. J Natl Cancer Inst 2000; 92:1641–50.
<https://doi.org/10.1093/jnci/92.20.1641>
17. ME, Mohamed M, Elwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation and amplification. Science 2001; 293:876–80.
<https://doi.org/10.1126/science.1062538>
18. ME, Sawyers CHL. Molecular mechanisms of resistance to STI 571 in chronic myeloid leukemia. Current Opin Hematol 2002; 9:303–7.
<https://doi.org/10.1097/00062752-200207000-00007>
19. S, Jörgensen H, Allan E et al. A significant proportion of CD 34+ progenitor cells survive exposure to STI 571 independent of their position in cell cycle. Blood 2001; 96:Abstr. 1482.
20. LT, Chung HM, Lin JY et al. Steven-Johnson syndrome after treatment with STI 571: a case report. Br J Haematol 2002; 117:620–2.
<https://doi.org/10.1046/j.1365-2141.2002.03499.x>
21. HM, Cortes J, O’Brien S. Imatinib mesylate (STI 571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99:3547–53.
<https://doi.org/10.1182/blood.V99.10.3547>
22. HM, O’Brien S. Cortes JE et al. Imatinib-mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood 2002; 100:1590–5.
23. HM, O’Brien SM, Keating M et al. Results of decitabine therapy in accelerated and blastic phases of chronic myelogenous leukemia. Leukemia 1997; 11:1617–20.
<https://doi.org/10.1038/sj.leu.2400796>
24. H, Sawyers C, Hochhaus A et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 246:645–52.
<https://doi.org/10.1056/NEJMoa011573>
25. HM, Smith TL, O’Brien SM et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon – alpha therapy. Ann Intern Med 1995; 122:254–61.
<https://doi.org/10.7326/0003-4819-122-4-199502150-00003>
26. HM, Talpaz M, O’Brien S et al. Dose escalation of imatinib mesylate can overcome resistance to standard dose therapy in patients with chronic myelogenous leukemia. Blood 2003; 101:473–5.
<https://doi.org/10.1182/blood-2002-05-1451>
27. HM, Talpaz M, Santini V et al. Homoharringtonine history, current research, and future directions. Cancer 2001; 92:1591–1604.
<https://doi.org/10.1002/1097-0142(20010915)92:6<1591::AID-CNCR1485>3.0.CO;2-U>
28. A. Chronic myeloid leukemia: current therapies and the potential role of farnesyl-transferase inhibitors. Semin Hematol 2002; 39(suppl.2):11–7.
<https://doi.org/10.1053/shem.2002.35979>
29. M, McLaughlin, Witte O et al. Induction of a chronic myelogenous leukemia – like syndrome in mice with V-abl and bcr/abl. Proc Natl Acad Sci USA 1990; 87:6659–63.
30. HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995; 86:2041–50.
31. JB, Watanabe SM, Singer JW et al. Cell lines and clinical isolates derived from Ph21–positive chronic myelogenous leukemia patients express C-abl proteins with a common structural alteration. Proc Natl Acad Sci USA 1985; 82:1810–14.
<https://doi.org/10.1073/pnas.82.6.1810>
<PubMed>
32. P, Tassi E, Varella–Garcia M et al. Induction of resistance to Abelson inihibitor STI 571 in leukemic cells through gene amplification. Blood 2000; 95:1758–66.
33. L, Frassoni F, Melo JV. Imatinib: can one outwit chronic myeloid leukemia? Haematologica 2002; 87:898–900.
34. L, Melo JV. Acquired resistance to imatinib mesylate: selection for preexisting mutant cells. Blood 2002; 100:1105.
<https://doi.org/10.1182/blood-2002-05-1578>
35. FX, Deininger MWN, Schultheis B et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to tyrosine kinase inhibitor STI 571: diverse mechanism of resistance. Blood 2000; 96:1070–9.
36. D, Marktel S, Bua M et al. The use of imatinib (STI 571) in chronic myeloid leukemia: some practical considerations. Haematologica 2002; 87:979–86.
37. MJ, O’Dwyer ME, Stone RM et al. Preliminary evaluation of the combination of imatinib mesylate (Gleevec) with low dose Ara-C as initial therapy for newly diagnosed chronic phase CML. Blood 2002; 100:Abstr. 617.
38. JV. The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype. Blood 1996; 88:2375–84.
39. PC, Hungerford DA. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 32:1497.
40. S, Kantarijan H, Keating M et al. Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 1995; 86:3322–6.
41. OG, Drucker BJ, Sawyers CHL et al. A phase 2 study of imatinib in patients with relapse or refractory Philadelphia chromosome-positive lymphoid leukemias. Hematol J 2002; 3:2–6.
<https://doi.org/10.1038/sj.thj.6200151>
42. – Ibarz J, Cathcart K, Korontsvit T et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95:1781–7.
43. C, Soenen-Cornu V, Grardel-Duffos N et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI 571, and they can pre-exist to the onset of treatment. Blood 2002; 100:1014–8.
<https://doi.org/10.1182/blood.V100.3.1014>
44. JD. A new consistent abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243:290–3.
<https://doi.org/10.1038/243290a0>
45. DG, Antman KH. Imatinib mesylate – a new oral target therapy. N Engl J Med 2002; 346:683–93.
<https://doi.org/10.1056/NEJMra013339>
46. CL, Hochhaus A, Feldman E et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crises: results of a phase II study. Blood 2002; 99:3530–9.
<https://doi.org/10.1182/blood.V99.10.3530>
47. T, Bornmann W, Pellicena P et al. Structural mechanisms for STI 571 inhibition of abelson tyrosine kinase. Science 2000; 289:1938–42.
<https://doi.org/10.1126/science.289.5486.1938>
48. X, Layton JE, Elefanty A et al. Comparison of effects of the tyrosine kinase inhibitors AG 957, AG 490, and STI 571 on BCR-ABL – expressing cells, demonstrating synergy between AG 490 and STI 571. Blood 2001; 97:2008–15.
<https://doi.org/10.1182/blood.V97.7.2008>
49. M, Kantarjian HM, Mc Credie K et al. Interferon – Alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991; 114:532–8.
<https://doi.org/10.7326/0003-4819-114-7-532>
50. M, McCredie KB, Mavligit GM et al. Leukocyte interferon-induced myeloid cytoreduction in myelogenous leukemia. Blood 1983; 62:689–92.
51. M, Silver RT, Drucker BJ. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002; 99:1928–37.
<https://doi.org/10.1182/blood.V99.6.1928>
52. AJ, Mahon FX, Lagarde V et al. Restoration of sensitivity to STI 571 – resistant chronic myeloid leukemia cells. Blood 2001; 98:3864–7.
<https://doi.org/10.1182/blood.V98.13.3864>
53. AS, Kantarjian H, Talpaz M. STI 571 in chronic myelogenous leukemia. Br J Haematol 2002; 119:15–24.
<https://doi.org/10.1046/j.1365-2141.2002.03899.x>
54. Voglová J, Poznarová A, Chrobák L et al. Imatinib mesylát (Glivec) v léčbě chronické myeloidní leukemie. Vnitř Lék 2003;43 (in press).
55. E, Griffin JD. Mechanism of resistance to the ABL tyrosine kinase inhibitor STI 571 in BCR/ABL – transformed hematopoietic cell lines. Blood 2000; 95:3498–505.
